

Comprehensive Cytogenetics of Fresh, Frozen, and FFPE Tissue with a Single Assay

- Surpass the breadth and depth of karyotyping, FISH, and CMA with a single, NGS-based assay
- Genome-wide cytogenomic information from FFPE, blood, solid tissue, and other sample types
- Analysis included, from sample to report
- Scalable, fast, and cost-effective without dedicated instrumentation

. 9g 9p -

ABL1

High-resolution mapping of genomic breakpoints

9g 9p -


ABL1

9c


22p

BCR

22



Genome-wide view of large-scale changes in chromosome structure




Chromosome-scale mapping of deletions, amplifications, and allele frequency

Homologous Recombination Deficiency (HRD) Assessment

ABL1

[chr22] chr9

90



Comprehensively capture genomic scarring


Cancers that demonstrate phenotypic homologous recombination deficiency (HRD) are candidates for treatment with drugs that exploit synthetic lethality. The OncoTerra Platform captures the range of genomic scars that result from HRD, including those that are difficult to detect with whole genome sequencing.

FFPE Applications

- The OncoTerra[™] Platform enables high-resolution cytogenomic analysis of solid tumors—samples that are unsuitable for traditional cytogenetics
- Identify balanced and unbalanced chromosomal aberrations including copy-neutral loss of heterozygosity (cnLOH); all with a fraction of sequencing costs associated with whole genome sequencing
- Identify novel and known druggable gene fusions and other indications for precision oncology therapies



Recover genome-wide insights from as little as 2 x 5 μm FFPE curls



The OncoTerra Platform is currently offered as a comprehensive sample-to-report service. Contact us to inquire about RUO kits compatible with existing low- and high-throughput sample processing pipelines.





info@phasegenomics.com www.phasegenomics.com Phone: 1-833-742-7436 Twitter: @PhaseGenomics

Unless otherwise stated, data on file.

For Research Use Only. Not for use in diagnostic procedures.

ONCOTERRA is a trademark of Phase Genomics, Inc. All other product names and trademarks are the property of their respective owners.

© 2022 Phase Genomics, Inc. All rights reserved.